Company: ERAS
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0000950170-25-042682
Chunk: 144

Company: Erasca, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 16
Chunk 144
---
2
     
    1.2

    10.13†
     
    Exclusive License Agreement, dated December 9, 2022 by and between Novartis Pharma AG and the Registrant
     
    10-K
     
    3/23/2023
     
    10.20

    10.14#
     
    Erasca, Inc. Non-Employee Director Compensation Program
     
    10-K
     
    3/27/2024
     
    10.18

    10.15†
     
    License Agreement, dated May 15, 2024, by and between Guangzhou Joyo Pharmatech Co., Ltd., and Erasca, Inc.
     
    10-Q
     
    8/12/2024
     
    10.1

    10.16†
     
    License Agreement, dated May 14, 2024, by and between Medshine Discovery Inc., and Erasca, Inc.
     
    10-Q
     
    8/12/2024
     
    10.2

    19.1
     
    Insider Trading Compliance Policy and Procedures

    X

    23.1
     
    Consent of KPMG LLP, independent registered public accounting firm

    X

143

    31.1
     
    Certification of Chief Executive Officer of Erasca, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

    X

    31.2
     
    Certification of Chief Financial Officer of Erasca, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

    X

    32.1*
     
    Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

    X

    32.2*
     
    Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

    X

    97
     
    Erasca, Inc. Policy for Recovery of Erroneously Awarded Compensation